Hematopoietic Development and Malignancy Program (HDMP)

Program Co-Leaders

• Laura Schuettpelz, MD, PhD
• Todd Fehniger, MD, PhD
• Geoffrey Uy, MD

Overview of the Program

The long-term goals of the Hematopoietic Development and Malignancy Program (HDMP) are to identify basic mechanisms regulating normal and malignant hematopoiesis, and develop innovative strategies to prevent, stratify, and treat hematopoietic malignancies. Working groups in leukemia, lymphoma, myeloma, and myelodysplastic syndromes/myeloproliferative neoplasms were established to develop, review, prioritize, and conduct translational research. Each working group is organized around three themes: cancer genomics, development of immunotherapies, and cancer biology. The HDMP fosters collaborative translational research and trains junior investigators through research seminars, journal clubs, work-in-progress meetings, and an annual retreat. Program leaders have identified areas of institutional strength and developed four specific translational aims.

Aims of the HDMP

The HDMP’s research efforts have been organized around three specific aims.

1. Develop fundamental immunology discoveries into novel immunotherapies for hematopoietic malignancies.
2. Leverage expertise in cancer genomics to identify key genetic and epigenetic alterations in hematopoietic malignancies and develop their translational potential.
3. Translate fundamental discoveries in hematopoietic cancer cell biology into novel strategies to treat hematopoietic malignancies and/or improve stem cell transplantation.
   

Recorded program seminars and events are available at this link on WUSTL Box.